Table 3.

Characteristics of the PWH who experienced virologic failure with the timeline of injections.

ID	Sex	Age (years)	BMI (kg/m2)	Timing of the blood sampling	Cabotegravir concentration (ng/mL)	Rilpivirine concentration (ng/mL)	HIV RNA (copies/mL)
1	Male	49	24	4 weeks after injection n°1, at Ctrough	2445	90	<50
				8 weeks after injection n°2, at Ctrough	1151	52	17,000
				4 weeks after injection n°3	2751	114	<50
				6 weeks after injection n°3	1128	77	<50
				Switch to bictegravir/emtricitabine/tenofovir alafenamide 6 weeks after injection n°3			<50
				10 weeks after injection n°3	120	65	<50
2	Male	33	24	2 weeks after injection n°1	1916	77	<50
				4 weeks after injection n°1, at Ctrough	1441	53	<50
				8 weeks after injection n°2, at Ctrough	712	25	<50
				8 weeks after injection n°3, at Ctrough	823	33	<50
				8 weeks after injection n°4, at Ctrough	1049	45	<50
				8 weeks after injection n°5, at Ctrough	109	36	<50
				8 weeks after injection n°6, at Ctrough	696	38	<50
				8 weeks after injection n°7, at Ctrough	704	55	549
3	Female	48	31	8 weeks after injection n°3, at Ctrough	239	4	62,000
				Switch to emtricitabine/tenofovir alafenamide/raltegravir			139
				Re-initiation of cabotegravir and rilpivirine 4 months later			<50
				4 weeks after injection n°1, at Ctrough	272	13	70
				3 weeks after injection n°2	402	19	<50
				8 weeks after injection n°2	–	–	<50
				Switch to doravirine/lamivudine/tenofovir disoproxil fumarate 7 weeks after injection n°4 due to persistent low-level viremia			61